Pancreatic Cancer Research

ResearcherHumanitas UniversityActive in the last 2 years

Armando Santoro

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1709-9492; OpenAlex author ID A5100766578, A5109739893. Sources: ClinicalTrials.gov.

Their work

Papers
9 (first author 0, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
37
Papers, trials and grants by year

2013: 1 paper · 2014: 1 trial · 2015: none · 2016: none · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 9

  1. Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 St… Co-author DOI 10.1158/2767-9764.crc-26-0018↗
  2. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Co-author DOI 10.1016/j.ejso.2024.109544↗
  3. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  4. Can STEreotactic Body Radiation Therapy (SBRT) Improve the Prognosis of Unresectable Locally Advanced Pancreatic Cancer? Long-Term Clinical Outcomes, Toxicity … Co-author DOI 10.3390/curroncol30070513↗
  5. Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. Last author DOI 10.1259/bjr.20190627↗
  6. Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND). Last author DOI 10.2217/fon-2019-0480↗
  7. Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective … Co-author DOI 10.1016/j.ejso.2016.12.012↗
  8. Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a … Co-author DOI 10.1177/1533034616650778↗
  9. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine… Co-author DOI 10.1016/j.ejca.2013.04.002↗

Trials 1

  1. Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy Principal investigator NCT02307500↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tiziana Comito · 4 shared papers, 2017–2023 · strength 0.36
  2. Marta Scorsetti · 4 shared papers, 2017–2023 · strength 0.36
  3. Silvia Bozzarelli · 3 shared papers, 2019–2023 · strength 0.35
  4. Alessandro Zerbi · 3 shared papers, 2017–2023 · strength 0.25
  5. Ronnie Shapira‐Frommer · 1 shared paper, 2026 · strength 0.23
  6. Tae Won Kim · 1 shared paper, 2026 · strength 0.23
  7. Mariano Ponz‐Sarvisé · 1 shared paper, 2026 · strength 0.23
  8. Giampaolo Tortora · 1 shared paper, 2026 · strength 0.23
  9. Robert C. Verdonk · 1 shared paper, 2025 · strength 0.16
  10. Lois A. Daamen · 1 shared paper, 2025 · strength 0.16
  11. Izaak Quintus Molenaar · 1 shared paper, 2025 · strength 0.16
  12. Johanna W. Wilmink · 1 shared paper, 2025 · strength 0.16
  13. Theo van Voorthuizen · 1 shared paper, 2025 · strength 0.16
  14. Merlijn U.J.E. Graus · 1 shared paper, 2025 · strength 0.16
  15. Fieke E. M. Froeling · 1 shared paper, 2025 · strength 0.16
  16. Bas Groot Koerkamp · 1 shared paper, 2025 · strength 0.16
  17. Judith de Vos‐Geelen · 1 shared paper, 2025 · strength 0.16
  18. Andrès M.R. Cervantes · 1 shared paper, 2025 · strength 0.16
  19. N C Biesma · 1 shared paper, 2025 · strength 0.16
  20. Hjalmar C. van Santvoort · 1 shared paper, 2025 · strength 0.16
  21. Andrew L. Coveler · 1 shared paper, 2025 · strength 0.16
  22. Peter J. Hosein · 1 shared paper, 2025 · strength 0.16
  23. Marc G. Besselink · 1 shared paper, 2025 · strength 0.16
  24. Davide Melisi · 1 shared paper, 2025 · strength 0.16
  25. Bruno Bockorny · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.